Open AccessFirst-line treatment of locally advanced HNSCC with double checkpoint inhibition and radiotherapy based on CD8+ T cell infiltration.
Author(s) -
Antoniu Oreste Gostian,
Markus Hecht,
Markus Eckstein,
Sandra Rutzner,
Jens von der Grün,
Thomas Illmer,
Matthias G. Hautmann,
Thomas Brunner,
Simon Laban,
Günther Klautke,
Bálint Tamaskovics,
Benjamin Frey,
Arndt Hartmann,
Claus Rödel,
Wilfried Budach,
Udo S. Gaipl,
R Fitkau,
Heinrich Iro
Publication year - 2020
Publication title -
laryngo-, rhino-, otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0040-1710955
Subject(s) - durvalumab , docetaxel , immunotherapy , cd8 , cisplatin , medicine , radiation therapy , tremelimumab , oncology , cancer research , infiltration (hvac) , nivolumab , chemotherapy , immune system , immunology , cancer , ipilimumab , physics , thermodynamics